ANI Pharmaceuticals, Inc. $ANIP Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC lowered its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 7.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 490,536 shares of the specialty pharmaceutical company’s stock after selling 37,740 shares during the period. William Blair Investment Management LLC owned 2.26% of ANI Pharmaceuticals worth $32,007,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Aberdeen Group plc lifted its holdings in ANI Pharmaceuticals by 76.1% during the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock worth $28,059,000 after buying an additional 181,134 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth about $11,144,000. Global Alpha Capital Management Ltd. raised its position in shares of ANI Pharmaceuticals by 17.8% during the 1st quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company’s stock worth $49,248,000 after acquiring an additional 111,040 shares in the last quarter. Parkman Healthcare Partners LLC purchased a new stake in ANI Pharmaceuticals during the first quarter worth approximately $7,030,000. Finally, Lisanti Capital Growth LLC boosted its holdings in ANI Pharmaceuticals by 291.8% in the first quarter. Lisanti Capital Growth LLC now owns 105,425 shares of the specialty pharmaceutical company’s stock valued at $7,058,000 after purchasing an additional 78,515 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Jeanne Thoma sold 21,540 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $89.15, for a total value of $1,920,291.00. Following the completion of the sale, the director owned 23,405 shares in the company, valued at approximately $2,086,555.75. This trade represents a 47.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $86.97, for a total transaction of $1,739,400.00. Following the completion of the sale, the senior vice president directly owned 173,226 shares in the company, valued at approximately $15,065,465.22. The trade was a 10.35% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 413,830 shares of company stock valued at $36,505,378. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st. JPMorgan Chase & Co. lifted their price target on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. Truist Financial boosted their price target on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. Weiss Ratings lowered ANI Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, October 8th. Finally, Piper Sandler reissued an “overweight” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $99.14.

ANI Pharmaceuticals Trading Up 3.1%

NASDAQ ANIP opened at $94.79 on Friday. The firm’s fifty day moving average is $92.70 and its two-hundred day moving average is $74.84. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $99.50. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. The firm has a market cap of $2.06 billion, a PE ratio of -123.10 and a beta of 0.58.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Thursday, June 8th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter. The business had revenue of $64.48 million for the quarter. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%. Analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.